2024³â 12¿ù 27ÀÏ ±Ý¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Business

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýÈ°

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óÇ°

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Galderma Launches Restylane VOLYME in China - One of the World¡¯s Fastest Growing Aesthetics Markets

Restylane VOLYME is designed for contouring and volumization of the mid-face region to support patients in achieving a youthful, revitalized look
´º½ºÀÏÀÚ: 2024-05-29

ZUG, SWITZERLAND -- Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane VOLYME in China. The company is also introducing its complementary Shape Up Holistic Individualized Treatment (HIT) in the country, which addresses aging concerns caused by loss of structural support in the mid-face. The availability of these targeted solutions for the mid-face region is demonstrative of Galderma’s commitment to meeting patient and injector needs in China. In the past decade, the growth of China’s aesthetics medicine market has outpaced the global market; with relatively low market penetration, there remains significant potential for future growth.[1]

Developed using Galderma’s proprietary OBT* gel technology, Restylane VOLYME is indicated for the correction of mid-face volume deficit and/or mid-face contour deficiency through injections into the subcutaneous to supraperiosteal layers of the skin.[2-3] Hyaluronic acid fillers are often patients’ first choice for mid-face augmentation and have been shown to deliver high patient satisfaction and long-lasting effects.[4] In China, hyaluronic acid fillers are among the top 10 most-sold aesthetics products.[1]

“We are delighted to deliver Galderma’s innovative aesthetics solutions in China with the support of our research and development teams, as well as local partners and regulatory authorities. As the Chinese market continues to expand, we look forward to working closely with all stakeholders to deliver our full, premium range of aesthetics products to meet the varied and individual needs of patients and injectors.”
GERRY MUHLE HEAD OF GLOBAL PRODUCT STRATEGY GALDERMA

Developed with a global community of injectors, the Shape Up HIT is the latest of Galderma’s HITs to be introduced in China, designed to create a common language to facilitate a two-way dialogue between patient and practitioner to align on patient priorities and keep satisfaction at the forefront.

“Aesthetic plastic surgery is an artistic creation under medical constraints, embodying a holistic and individualized approach. Facial expressions are controlled by 42 muscles which convey emotions such as joy, anger, sorrow, and happiness. These muscles are also involved in language, chewing, and other activities. The appearance of the mid-face is crucial in interpersonal communication. Together, Restylane VOLYME and the Shape Up HIT enable patients to maintain their natural facial expressions while also supporting injectors to deliver a youthful and long-lasting aesthetic effect.”
PROFESSOR HAIYAN CUI DIRECTOR OF THE INSTITUTE OF AESTHETIC PLASTIC SURGERY AND MEDICINE TONGJI UNIVERSITY DIRECTOR OF THE PLASTIC & COSMETIC SURGERY DEPARTMENT TONGJI HOSPITAL OF TONGJI UNIVERSITY

HIT is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction. The Balanced Profile HIT was Galderma’s first HIT to be introduced in China in 2023, providing a framework for practitioners to conduct a full objective facial assessment for the patient and help bring balance to their profile. HIT naturally springboards from Galderma’s AART (Assessment, Anatomy, Range, Treatment) methodology for a new generation of individualized aesthetics.

Restylane is the largest and most diverse range of individually engineered hyaluronic acid fillers on the market, approved in more than 80 countries and regions, and with over 65 million treatments administered worldwide.[5-8]



 Àüü´º½º¸ñ·ÏÀ¸·Î

CSC Strengthens Leadership in Funds and Capital Markets Division with Two Key Appointments
Infobip Data Reveals Record Black Friday and Cyber Week Communications Interactions in APAC
CompareForexBrokers Announces 2025 Annual Award Winners
June Yang Appointed to MSCI Inc. Board of Directors
Kinaxis Named a Leader in three IDC MarketScape reports
Andersen Global Expands Service Offerings in Japan with Addition of Kohwa Sohgoh
Experian¡¯s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks

 

NIQ Research Uncovers Hidden Consumer Attitudes Toward AI-Generated Ad...
AIT Worldwide Logistics Secures ISO Quality, Safety, and Sustainabilit...
The Rigaku Group¡¯s XwinSys Changes its Name to Rigaku Semiconductor I...
RFR Celebrates 2024 Deal Highlights in NYC and Miami
Millennials drive the highest growth at US$193 Billion overtaking Gen ...
Bureau Veritas Enters the CAC 40 Paris Stock Index
METAZ Joins Aptos Movementum Accelerator to Transform the Future of To...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚÇ¥±â 'ãæÚ¤ó¢'
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á
¾Ë¶ã°Ç¼³, »óÇ¥µî·Ï ¿Ï·á
Á¸Â÷´åÄÄ, ±Û²Ã º¯°æ »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇÑ°è¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, Æѽº 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..